Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 1, 2004, Pages 57-65

  Baca, Enrique ^a   Garcia Garcia, Margarida ^b   Porras Chavarino, Alberto ^c  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Project Management Department   (Spain)

^c PFIZER INC   (United States)

Author keywords

Depressive disorder; Dysthymic disorder; Gender differences; Imipramine; Sertraline

Indexed keywords

IMIPRAMINE; SERTRALINE;

ACUTE DIARRHEA; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG RESPONSE; DRUG TOLERABILITY; DYSTHYMIA; FEMALE; GASTRITIS; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; INSOMNIA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PSYCHOLOGIC ASSESSMENT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREMOR; XEROSTOMIA;

EID: 0346103861     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00177-5     Document Type: Article

References (46)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. (revised) 3rd ed. 1987;American Psychiatric Association, Washington.
2. Angst J., Dobler-Mikola A. Do the diagnostic criteria determine the sex ratio in depression? J. Affect. Disord. 7:1984;189-198.
3. Armitage R., Hoffmann R.F. Sleep EEG, depression and gender. Sleep Med. Rev. 5(3):2001;237-246.
4. Canetto S.S., Sakinofsky I. The gender paradox in suicide. Suicide Life-Threat. Behav. 28:1998;1-23.
5. Clayton A. Panic in women across the life cycle: clinical presentation and response to sertraline. Annual Meeting of 154rd American Psychiatric Association. New Orleans, LA, NR 597:2001.
6. Ensom M.H. Gender-based differences and menstrual cycle-related changes in specific diseases: implications for pharmacotherapy. Pharmacotherapy. 20:2000;523-539.
7. Frackiewicz E.J., Sramek J.J., Cutler N.R. Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann. Pharmacother. 34:2000;80-88.
8. Frank E., Carpenter L.L., Kupfer D.J. Sex differences in recurrent depression: are there any that are significant? Am. J. Psychiatry. 145:1988;41-45.
9. Gex-Fabry M., Balant-Gorgia A.E., Balant L.P., Garrone G. Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin. Pharmacokinet. 19:1990;241-255.
10. Glassman A.H., Perel J.M., Shostak M., Kantor S.J., Fleiss J.L. Clinical implications of imipramine plasma levels for depressive illness. Arch. Gen. Psychiatry. 34:1977;197-204.
11. Gold J.H. Gender differences in psychiatric illness and treatments: a critical review. J. of Nerv. Ment. Dis. 186:1998;769-775.
12. Greenblatt D.J., Friedman H., Burstein E.S., Scavone J.M., Blyden G.T., Ochs H.R., Miller L.G., Harmatz J.S., Shader R.I. Trazodone kinetics: effect of age, gender, and obesity. Clin. Pharmacol. Ther. 42:1987;193-200.
13. Guy W. Clinical global impressions. Guy W. Early Clinical Drug Evaluation (ECDEU). Assessment Manual for Psychopharmacology. 1976;217-222 NIMH, Rockville.
14. Halbreich U., Kahn L.S. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 15(10):2001;797-817.
15. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
16. Hamilton M. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6:1967;278-296.
17. Hamilton J.A., Grant M., Jensvold M.F. Sex and treatment of depressions: when does it matter? Jensvold M.F., Halbreich U., Hamilton J.A. Psychopharmacology and Women: Sex, Gender, and Hormones. 1996;241-257 American Psychiatric Press, Washington.
18. Isometsa E.T., Henriksson M.M., Aro H.M., Heikkinen M.E., Kuoppasalmi K.I., Lonnqvist J.K. Suicide in major depression. Am. J. Psychiatry. 151:1994;530-536.
19. Kennedy S.H., Eisfeld B.S., Dickens S.E., Bacchiochi J.R., Bagby R.M. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and velafaxine. J. Clin. Psychiatry. 61:2000;276-281.
20. Kessler R.C., Brown R.L., Broman C.L. Sex differences in psychiatric help-seeking: evidence from four large-scale surveys. J. Health Soc. Behav. 22:1981;49-64.
21. Kessler R.C., McGonagle K.A., Swartz M., Blazer D.G., Nelson C.B. Sex and depression in the National Comorbidity Survey: I. Lifetime, prevalence, chronicity, and recurrance. J. Affect. Disord. 29:1993;85-96.
22. Kornstein S.G. Gender differences in depression: implications for treatment. J. Clin. Psychiatry. 58(Suppl. 15):1997;12-18.
23. Kornstein S.G., McEnany G. Enhancing pharmacologic effects in the treatment of depression in women. J. Clin. Psychiatry. 61(Suppl. 11):2000;18-27.
24. Kornstein S.G., Schatzberg A.F., Yonkers K.A., Thase M.E., Keitner G.I., Ryan C.E., Schlager D. Gender differences in presentation of chronic major depression. Psychopharmacol. Bull. 31:1996;711-718.
25. Kornstein S.G., Shatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., Keller M.B. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am. J. Psychiatry. 157:2000;1445-1452.
26. Kornstein S.G., Shatzberg A.F., Thase M.E., Yonkers K.A., McCullough J.P., Keitner G.I., Gelenberg A.J., Davis S.M., Harrison W.M., Keller M.B. Dr Kornstein and collegues reply (letter). Am. J. Psychiatry. 158:2001;1532-1533.
27. Kornstein S.G., Schatzberg A.F., Thase M.E., Svikis D., Gelenberg A.J., Keitner G.I., Borian F.E. Gender differences in response to combination treatment for chronic depression. Annual Meeting of 155rd American Psychiatric Association. Philadelphia, NR 249:2002.
28. Maier W., Gänsicke M., Rezaki M., Tiemens B., Urzúa R.F. Gender differences in the prevalence of depression: a survey in primary care. J. Affect. Disord. 53:1999;241-252.
29. Marazziti D., Rossi A., Palengo L., Barsanti A., Carrai M., Giannaccini G., Serra P., Lucacchini A., Cassano G.B. Effect of aging and sex on the [3H]-paroxetine binding to human platelets. J. Affect. Disord. 50:1998;11-15.
30. Martényi F., Dossenbach M., Mraz K., Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotoninergic or norepinephrinergic reuptake inhibition profile. Eur. Neuropsychopharmacol. 11:2001;227-232.
31. Montejo A.L., Llorca G., Izquierdo J.A., Ledesma A., Bousoño M., Calcedo A., Carrasco J.L., Ciudad J., Daniel E., De la Gándara J., Derecho J., Franco M., Gómez M.J., Macías J.A., Martín T., Pérez V., Sánchez J.M., Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther. 23:1997;176-194.
32. Moody J.P., Tait A.C., Todrick A. Plasma levels of imipramine and desmethy limipramine during therapy. Br. J. Psychiatry. 113:1967;183-193.
33. Murphy G.E. Why women are less likely than men to commit suicide. Compr. Psychiatry. 39:1998;165-175.
34. Neuger J., El Khoury A., Kjellman B.F., Wahlund B., Aberg-Wistedt A., Stain-Malmgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res. 85:1999;189-198.
35. Preskorn S.H., Mac D.S. Plasma levels of amitriptyline: effects of age and sex. J. Clin. Psychiatry. 46:1985;276-277.
36. Quitkin F.M., Stewart J.W., McGrath P.J. Gender differences in treatment response (letter). Am. J. Psychiatry. 158:2001;1531-1532.
37. Raskin A. Age-sex differences in response to antidepressant drugs. J. of Nerv. Ment. Dis. 159:1974;120-130.
38. Regier D.A., Boyd J.H., Burke J.D. Jr., Rae D.S., Myers J.K., Kramer M., Robins L.N., George L.K., Karno M., Locke B.Z. One-month prevalence of mental disorders in the United States: based on five epidemiologic catchment area sites. Arch. Gen. Psychiatry. 45:1988;977-986.
39. Silverstein B. Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am. J. Psychiatry. 156:1999;480-482.
40. Temple R., Ellenberg S.S. Placebo-controlled trials and active-control trials in the evaluation of new treatments: Part 1. Ethical and scientific issues. Ann. Intern. Med. 133:2000;455-463.
41. Thase M.E., Reynolds C.F., Frank E., Simons A.D., McGeary J., Fasiczka A.L., Garamoni G.G., Jennings J.R., Kupfer D.J. Do depressed men and women respond similarly to cognitive behavior therapy? Am. J. Psychiatry. 151:1994;500-505.
42. Thase M.A., Frank E., Korsntein S., Yonkers K.A. Gender differences in response to treatments of depression. Frank E. Gender and Its Effects on Psychopathology. 2000;103-125 American Psychiatric Press, Washington.
43. Videbech P., Ravnkilde B., Pedersen A.R., Egander A., Landbo B., Rasmussen N.A., Andersen F., Stodkilde-Jorgensen H., Gjedde A., Rosenberg R. The Danish PET/depression project: PET findings in patients with major depression. Psychol. Med. 31(7):2001;1147-1158.
44. Weissman M.M., Band R., Joyce P.R., Newman S., Wells J.E., Witchen H.U. Sex differences in rates of depression: cross-national perspectives. J. Affect. Disord. 29:1993;77-84.
45. World Health Organization Classification of Mental and Behavioural Disorders. 10th ed. 1992;World Health Organization, Geneva.
46. World Medical Association Declaration of Helsinki, 41st World Medical Assembly, Hong Kong:1989.